(Q34576923)

3 August 2017

1 reference

title

The pharmacogenetics of asthma: a candidate gene approach (English)

1 reference

3 August 2017

0 references

Silverman ES

1

1 reference

3 August 2017

Liggett SB

2

1 reference

3 August 2017

Gelfand EW

3

1 reference

3 August 2017

Rosenwasser LJ

4

1 reference

3 August 2017

Baron RM

5

1 reference

3 August 2017

Bolk S

6

1 reference

3 August 2017

Weiss ST

7

1 reference

3 August 2017

Drazen JM

8

1 reference

3 August 2017

language of work or name

1 reference

1 January 2001

1 reference

The Pharmacogenomics Journal

3 August 2017

published in

1 reference

3 August 2017

volume

1

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

27-37

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500005

3 August 2017

exact match

0 references

cites work

TH2-type cytokines in asthma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Mediator and cytokine mechanisms in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Evidence for multiple genetic susceptibility loci for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Heterogeneity of therapeutic responses in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

The use of beta-agonists and the risk of death and near death from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Regular inhaled beta-agonist treatment in bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Glucocorticoid receptors: ATP and cell cycle dependence, phosphorylation, and hormone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

The glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Abnormal glucocorticoid receptor gene and mRNA in primary cortisol resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Steroid-resistant asthma: immunologic and pharmacologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

The genetics of asthma and atopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Association of asthma and the interleukin-4 promoter gene in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and Inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Leukotrienes and lipoxins: structures, biosynthesis, and biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Treatment of asthma with drugs modifying the leukotriene pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Biology and pathophysiology of leukotrienes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Characterization of the human 5-lipoxygenase gene promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

The glutamine 27 β-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

Association between - 308 tumour necrosis factor promoter polymorphism and bronchial hyperreactivity in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Regulation of second messengers associated with airway smooth muscle contraction and relaxation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Polymorphisms of the IL-4, TNF-alpha, and Fcepsilon RIbeta genes and the risk of allergic disorders in at-risk infants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Lipoxygenases as therapeutic targets in the acute and subacute phases of glomerular immune injury.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500005

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500005

1 reference

Dimensions Publication ID

3 August 2017

1044427117

0 references

1 reference